ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
81,595
0,98%
Bitcoin
68 427,00
1,00%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. XOMA Corporation (XOMA)

  7. XOMA Corporation (XOMA) Actualités

XOMA

XOMA (XOMA)

XOMA Corporation
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:XOMA
DateHeureSourceTitreSymboleSociété
14/05/202413h30GlobeNewswire Inc.XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQNASDAQ:XOMAXOMA Corporation
09/05/202413h30GlobeNewswire Inc.XOMA Reports First Quarter 2024 Financial Results and Highlights Recent ActivitiesNASDAQ:XOMAXOMA Corporation
30/04/202413h30GlobeNewswire Inc.XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%NASDAQ:XOMAXOMA Corporation
25/04/202413h30GlobeNewswire Inc.XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)NASDAQ:XOMAXOMA Corporation
24/04/202415h00PR Newswire (US)Actym Therapeutics Appoints Thomas Smart as CEONASDAQ:XOMAXOMA Corporation
03/04/202415h00GlobeNewswire Inc.XOMA Corporation Announces Closing of Tender OfferNASDAQ:XOMAXOMA Corporation
21/03/202412h30GlobeNewswire Inc.XOMA Declares Quarterly Preferred Stock DividendsNASDAQ:XOMAXOMA Corporation
19/03/202421h05GlobeNewswire Inc.XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.NASDAQ:XOMAXOMA Corporation
08/03/202413h30GlobeNewswire Inc.XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder ValueNASDAQ:XOMAXOMA Corporation
28/02/202413h30GlobeNewswire Inc.XOMA to Present at Upcoming Investor Conferences in MarchNASDAQ:XOMAXOMA Corporation
16/02/202414h00GlobeNewswire Inc.XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value RightNASDAQ:XOMAXOMA Corporation
18/01/202414h30GlobeNewswire Inc.XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® AcquisitionNASDAQ:XOMAXOMA Corporation
11/01/202422h50Dow Jones NewsXoma to Make $1 Million Milestone Payment to LadRx After FDA Accepts Zevra Application for ArimoclomolNASDAQ:XOMAXOMA Corporation
11/01/202422h05GlobeNewswire Inc.FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRxNASDAQ:XOMAXOMA Corporation
08/01/202413h30GlobeNewswire Inc.XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of DirectorsNASDAQ:XOMAXOMA Corporation
02/01/202413h30GlobeNewswire Inc.XOMA Announces Stock Repurchase Program of up to $50 MillionNASDAQ:XOMAXOMA Corporation
19/12/202313h30GlobeNewswire Inc.XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® RoyaltiesNASDAQ:XOMAXOMA Corporation
07/11/202313h30GlobeNewswire Inc.XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder ValueNASDAQ:XOMAXOMA Corporation
31/10/202312h30GlobeNewswire Inc.XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)NASDAQ:XOMAXOMA Corporation
06/09/202313h30GlobeNewswire Inc.XOMA to Present at H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:XOMAXOMA Corporation
08/08/202313h30GlobeNewswire Inc.XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization StrategyNASDAQ:XOMAXOMA Corporation
24/06/202300h14GlobeNewswire Inc.XOMA Added to the Russell 2000® and Russell 3000® IndexesNASDAQ:XOMAXOMA Corporation
22/06/202313h30GlobeNewswire Inc.XOMA Acquires Royalty and Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) and Phase 2 Oncology AssetNASDAQ:XOMAXOMA Corporation
25/05/202322h34Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XOMAXOMA Corporation
18/05/202323h23Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:XOMAXOMA Corporation
09/05/202313h36Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:XOMAXOMA Corporation
09/05/202313h30GlobeNewswire Inc.XOMA Reports First Quarter 2023 Financial Results and Provides Update on the Acceleration of its Differentiated Royalty Monetization StrategyNASDAQ:XOMAXOMA Corporation
26/04/202313h30GlobeNewswire Inc.XOMA to Present at H.C. Wainwright BioConnect Investor ConferenceNASDAQ:XOMAXOMA Corporation
04/04/202322h20Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:XOMAXOMA Corporation
30/03/202313h30GlobeNewswire Inc.XOMA Acquires Cashflow-Generating Asset for its Royalty and Milestone PortfolioNASDAQ:XOMAXOMA Corporation
 Showing the most relevant articles for your search:NASDAQ:XOMA

Dernières Valeurs Consultées

BIT
SDIV
Global X Superdividend U...
BIT
CL2
CASAM ETF Leveraged MSCI...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés